BIOL Biolase Inc

Price (delayed)

$0.7369

Market cap

$110.83M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.39

Enterprise value

$87.76M

Highlights
Biolase's quick ratio has soared by 110% from the previous quarter
The company's EPS rose by 47% YoY and by 30% QoQ
BIOL's gross profit is down by 38% year-on-year but it is up by 22% since the previous quarter
Biolase's gross margin has decreased by 23% YoY but it has increased by 7% from the previous quarter
BIOL's debt is up by 33% year-on-year

Key stats

What are the main financial stats of BIOL
Market
Shares outstanding
150.4M
Market cap
$110.83M
Enterprise value
$87.76M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.28
Price to sales (P/S)
3.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.36
Earnings
Revenue
$26.11M
EBIT
-$15.18M
EBITDA
-$14.77M
Free cash flow
-$15.26M
Per share
EPS
-$0.39
Free cash flow per share
-$0.11
Book value per share
$0.22
Revenue per share
$0.19
TBVPS
$0.45
Balance sheet
Total assets
$63.48M
Total liabilities
$29.97M
Debt
$17.98M
Equity
$33.52M
Working capital
$46.48M
Liquidity
Debt to equity
0.54
Current ratio
5.12
Quick ratio
3.93
Net debt/EBITDA
1.56
Margins
EBITDA margin
-56.6%
Gross margin
29%
Net margin
-67.9%
Operating margin
-73.7%
Efficiency
Return on assets
-40.7%
Return on equity
-120.8%
Return on invested capital
-72%
Return on capital employed
-29.1%
Return on sales
-58.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIOL stock price

How has the Biolase stock price performed over time
Intraday
-1.48%
1 week
-12.27%
1 month
-0.42%
1 year
50.39%
YTD
75.45%
QTD
-12.27%

Financial performance

How have Biolase's revenue and profit performed over time
Revenue
$26.11M
Gross profit
$7.56M
Operating income
-$19.25M
Net income
-$17.73M
Gross margin
29%
Net margin
-67.9%
The operating margin has declined by 43% year-on-year but it has grown by 9% since the previous quarter
BIOL's gross profit is down by 38% year-on-year but it is up by 22% since the previous quarter
Biolase's gross margin has decreased by 23% YoY but it has increased by 7% from the previous quarter
Biolase's revenue has decreased by 19% YoY but it has increased by 15% from the previous quarter

Growth

What is Biolase's growth rate over time

Valuation

What is Biolase stock price valuation
P/E
N/A
P/B
3.28
P/S
3.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.36
The company's EPS rose by 47% YoY and by 30% QoQ
BIOL's price to book (P/B) is 47% less than its 5-year quarterly average of 6.2 and 37% less than its last 4 quarters average of 5.2
The stock's price to sales (P/S) is 111% more than its last 4 quarters average of 1.8
Biolase's revenue has decreased by 19% YoY but it has increased by 15% from the previous quarter

Efficiency

How efficient is Biolase business performance
BIOL's ROE has soared by 64% QoQ
The return on assets has increased by 37% year-on-year and by 18% since the previous quarter
Biolase's ROIC has increased by 27% YoY and by 15% from the previous quarter
The company's return on sales fell by 12% YoY but it rose by 8% QoQ

Dividends

What is BIOL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIOL.

Financial health

How did Biolase financials performed over time
The company's total assets is 112% higher than its total liabilities
The company's total assets has surged by 159% YoY and by 55% QoQ
Biolase's quick ratio has soared by 110% from the previous quarter
BIOL's debt is 46% smaller than its equity
The debt to equity has soared by 119% YoY but it has plunged by 70% from the previous quarter
BIOL's debt is up by 33% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.